Bioprocessing, Bioengineering and Process Chemistry in the Biopharmaceutical Industry

Kumar Gadamasetti is currently the founder-CEO of Certum Bio located in the San Francisco Bay area in CA-USA. Current interests are in the area of small molecules as well as biologics including Antibody Drug Conjugates (ADCs), building blocks of DNA and expanded genetic alphabet, repurposing existing drugs and process chemistry related to biologics and small molecules. His professional career began at Bristol-Myers Squibb Co, followed by Amgen, Discovery Partners International, X-Mine. He was the founder of Delphian Pharmaceuticals and Certum LLC. He obtained his Ph.D. (1987) from the University of Vermont in organic chemistry of cancer drugs and precursors and has done post-doctoral work at the University of Virginia. He was the founder-chairman (2002-2004) of ACS Prospectives, ‘Process Chemistry in the Pharmaceutical Industry’. He was the editor of two volumes titled, ‘Process Chemistry in the Pharmaceutical Industry’ (ISBN# 0-8247-1981-6, 1999) and ‘Process Chemistry in the Pharmaceutical Industry: Challenges in an Ever-Changing Climate’ (ISBN#13:978-0-8493-9051-7, 2007). Kumar has been a visiting professor at Catholic University at Louvain, Brussels, Belgium and the Univ. of Pittsburgh, PA-USA and was the invited speaker at Humboldt University, Berlin, Germany. His major accomplishments include his contributions on the development of drug substance (API) and the drug product that helped along with the respective team members in launching three products to marketing: 1. Paclitaxel® (Bristol-Myers Squibb) 2. Sensipar® (Amgen) and 3. Duexis® (Horizon Therapeutics).Stephen A. Kolodziej is an Associate Research Fellow in the Biotherapeutics Pharmaceutical Sciences division of Pfizer at the Chesterfield Missouri site. His group develops downstream manufacturing processes for biotherapeutic drug and vaccine candidates, specializing in protein conjugates. He made major contributions to process and product understanding on many late-stage bacterial vaccine projects, leading to the commercialization of Prevnar 20® and Penbraya®. He started his professional career as a medicinal chemist in Searle, Pharmacia, and then Pfizer developing novel small molecule candidates for the treatment of inflammation, cancer, and cardiovascular disease. He applied the tools of combinatorial chemistry to produce small libraries of candidates for evaluation in numerous preclinical programs and was a coinventor for Xalkori®, an ALK inhibitor approved for the treatment of non-small cell lung cancer. Steve has a BA and a PhD in Organic Chemistry from the University of Missouri-St. Louis with Professor Rudolph E. K. Winter on the synthesis of natural products.

• Bioprocessing, Bioengineering and Process Chemistry in the Biopharmaceutical Industry Using Chemistry and Bioengineering to Improve the Performance of Biologics An Overview.- Synthetic Biology in Drug Development and Beyond.- Increasing the Scalability of DNA Synthesis and Its Key Role in Expanding the Biopharmaceutical Discovery Process.- Advancements in the Manufacture of Monoclonal Antibodies and other Large Molecule Protein Therapeutics Recent Innovations in Cell Culture Technology Enabling Process Intensification.- Process Development and Manufacturing Considerations for Multispecific (Bispecific and Trispecific) Antibodies Case Studies.- Metabolic and process engineering to control glycan structures for biopharmaceuticals produced in cultured mammalian cells.- Even A Worm Will Turn Immunity Following AAV Vector Administration.- COVID-19 Vaccine Manufacturing Processes Making the Molecules to Solve the Pandemic.- CAR T Bioprocessing.- CRISPR Technology and its Application in Therapeutics.- Fusion Proteins Current Status and Future Perspectives.- Development of Antibody Drug Conjugates.- Mylotarg The Journey to FDA Reapproval and Broad International Approval.- Biopharmaceutical Informatics A Strategic Vision for Discovering Developable Biotherapeutic Drug Candidates.- Advanced Data Analytics Application in Bio manufacturing Processes.- Overview of Complexities of Global CMC Regulatory Affairs.- CMC Considerations for Continuous Bioprocess Design, Development and Manufacturing.- Three Decades of Advancements in Technical Transfer of Biologics a Blueprint for Advanced Therapeutics.- Emerging Biopharmaceutical Technologies and Trends.